The board of Fredun Pharmaceuticals at its meeting held on 29 December 2025 has approved allotment of 6,44,360 equity shares at an issue price of Rs 1250 (including a premium of Rs 1240) on preferential basis for a cash consideration of Rs 80.54 crore payable in cash;

The board also approved allotment of 5,51,600 convertible warrants at an exercise price of Rs 1250 per warrant aggregating to Rs 68.95 crore, upon receipt of Rs 312.50 (being 25% of the issue price of warrant) amounting to Rs 17.23 crore as subscription price.